

Anu Jacob

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10985890/publications.pdf>

Version: 2024-02-01

92
papers

10,164
citations

61984

43
h-index

45317

90
g-index

94
all docs

94
docs citations

94
times ranked

5929
citing authors

#	ARTICLE	IF	CITATIONS
1	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. <i>Neurology</i> , 2015, 85, 177-189.	1.1	3,275
2	Clinical presentation and prognosis in MOG-antibody disease: a UK study. <i>Brain</i> , 2017, 140, 3128-3138.	7.6	527
3	Treatment of Neuromyelitis Optica With Rituximab. <i>Archives of Neurology</i> , 2008, 65, 1443.	4.5	445
4	Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. <i>Brain</i> , 2012, 135, 1834-1849.	7.6	361
5	Treatment of Neuromyelitis Optica With Mycophenolate Mofetil. <i>Archives of Neurology</i> , 2009, 66, 1128-33.	4.5	283
6	Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology</i> , The, 2021, 20, 762-772.	10.2	261
7	Aquaporin-4 Antibodies in Neuromyelitis Optica and Longitudinally Extensive Transverse Myelitis. <i>Archives of Neurology</i> , 2008, 65, 913-9.	4.5	259
8	Treatment of neuromyelitis optica: Review and recommendations. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 180-187.	2.0	217
9	Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. <i>Frontiers in Neurology</i> , 2020, 11, 501.	2.4	216
10	An Approach to the Diagnosis of Acute Transverse Myelitis. <i>Seminars in Neurology</i> , 2008, 28, 105-120.	1.4	210
11	Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease. <i>JAMA Neurology</i> , 2018, 75, 65.	9.0	184
12	Neurological update: MOG antibody disease. <i>Journal of Neurology</i> , 2019, 266, 1280-1286.	3.6	171
13	What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. <i>Journal of Neurology</i> , 2017, 264, 2088-2094.	3.6	168
14	Neuromyelitis optica spectrum disorders. <i>Clinical Medicine</i> , 2019, 19, 169-176.	1.9	163
15	Antibodies to GABA _A receptor $\alpha 1$ and $\alpha 2$ subunits. <i>Neurology</i> , 2015, 84, 1233-1241.	1.1	159
16	Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 922-930.	1.9	149
17	Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 132-136.	1.9	132
18	Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. <i>Brain</i> , 2019, 142, 1310-1323.	7.6	131

#	ARTICLE	IF	CITATIONS
19	Area postrema syndrome. <i>Neurology</i> , 2018, 91, e1642-e1651.	1.1	129
20	Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. <i>Muscle and Nerve</i> , 2009, 39, 87-90.	2.2	123
21	Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. <i>Multiple Sclerosis Journal</i> , 2014, 20, 501-504.	3.0	115
22	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102251.	2.0	110
23	A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica. <i>Autoimmunity</i> , 2014, 47, 154-161.	2.6	109
24	Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1533-1540.	3.0	107
25	Neuromyelitis optica: Changing concepts. <i>Journal of Neuroimmunology</i> , 2007, 187, 126-138.	2.3	104
26	Worldwide Incidence and Prevalence of Neuromyelitis Optica. <i>Neurology</i> , 2021, 96, 59-77.	1.1	101
27	Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features: Table 1. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 470-472.	1.9	90
28	Does natalizumab therapy worsen neuromyelitis optica?. <i>Neurology</i> , 2012, 79, 1065-1066.	1.1	85
29	The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. <i>Journal of Neurology</i> , 2013, 260, 2134-2137.	3.6	85
30	Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 918-921.	1.9	84
31	Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. <i>Journal of Neurology</i> , 2006, 253, 1160-1164.	3.6	80
32	Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations. <i>Practical Neurology</i> , 2019, 19, 187-195.	1.1	78
33	Value of the central vein sign at 3T to differentiate MS from seropositive NMOSD. <i>Neurology</i> , 2018, 90, e1183-e1190.	1.1	71
34	Neuropathic pruritus (itch) in neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2013, 19, 475-479.	3.0	70
35	Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	6.0	64
36	Neuropathic pain in neuromyelitis optica affects activities of daily living and quality of life. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1658-1661.	3.0	63

#	ARTICLE	IF	CITATIONS
37	Cognitive and psychiatric comorbidities in neuromyelitis optica. <i>Journal of the Neurological Sciences</i> , 2016, 360, 4-9.	0.6	61
38	Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. <i>Journal of Neurology</i> , 2016, 263, 140-149.	3.6	60
39	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2015, 72, 815.	9.0	59
40	Rituximab in neurological disease: principles, evidence and practice. <i>Practical Neurology</i> , 2019, 19, 5-20.	1.1	59
41	Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab. <i>Journal of the Neurological Sciences</i> , 2014, 339, 223-225.	0.6	58
42	The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates. <i>Multiple Sclerosis Journal</i> , 2017, 23, 228-233.	3.0	53
43	A practical guide to the treatment of neuromyelitis optica. <i>Practical Neurology</i> , 2012, 12, 209-214.	1.1	51
44	Retinal Optical Coherence Tomography in Neuromyelitis Optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	47
45	Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the United Kingdom. <i>JAMA Network Open</i> , 2022, 5, e2142780.	5.9	46
46	Chronic neuropathic pain severity is determined by lesion level in aquaporin 4-antibody-positive myelitis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 165-169.	1.9	37
47	Detrimental role of granulocyte-colony stimulating factor in neuromyelitis optica: clinical case and histological evidence. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1801-1803.	3.0	36
48	Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e339.	6.0	32
49	Bladder and bowel dysfunction affect quality of life. A cross sectional study of 60 patients with aquaporin-4 antibody positive Neuromyelitis Optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 614-618.	2.0	31
50	Facial Onset Sensory and Motor Neuronopathy: Further Evidence for a TDP-43 Proteinopathy. <i>Case Reports in Neurology</i> , 2015, 7, 95-100.	0.7	30
51	Predictors of relapse in MOG antibody associated disease: a cohort study. <i>BMJ Open</i> , 2021, 11, e055392.	1.9	30
52	Life on hold: the experience of living with neuromyelitis optica. <i>Disability and Rehabilitation</i> , 2014, 36, 1100-1107.	1.8	28
53	Longitudinally extensive transverse myelitis as the sole presentation of neuro-Behçet's disease responding to infliximab. <i>Journal of Spinal Cord Medicine</i> , 2012, 35, 122-124.	1.4	26
54	What's new in neuromyelitis optica? A short review for the clinical neurologist. <i>Journal of Neurology</i> , 2017, 264, 2330-2344.	3.6	26

#	ARTICLE	IF	CITATIONS
55	AgOTf-catalyzed dehydrative [3+2] annulation of aziridines with 2-naphthols. <i>Chemical Communications</i> , 2017, 53, 8219-8222.	4.1	26
56	Metal-Free, Brønsted Acid-Catalyzed Formal [3+2] Annulation of Quinone Monoacetals with 2-Naphthols. <i>Journal of Organic Chemistry</i> , 2017, 82, 11269-11274.	3.2	23
57	Occurrence of CNS demyelinating disease in patients with myasthenia gravis. <i>Neurology</i> , 2007, 68, 1326-1327.	1.1	21
58	Rituximab abrogates aquaporin-4-specific germinal center activity in patients with neuromyelitis optica spectrum disorders. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	21
59	A multicentre randomised controlled TRial of IntraVENous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE). <i>Health Technology Assessment</i> , 2017, 21, 1-50.	2.8	20
60	Longitudinal Retinal Changes in <scp>MOGAD</scp>. <i>Annals of Neurology</i> , 2022, 92, 476-485.	5.3	20
61	Transverse Myelitis Associated With an Itchy Rash and HyperCKemia. <i>JAMA Neurology</i> , 2014, 71, 630.	9.0	18
62	Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review. <i>Journal of Neurology</i> , 2021, 268, 1643-1664.	3.6	18
63	Does mitochondrial DNA predispose to neuromyelitis optica (Devic's disease)? <i>Brain</i> , 2008, 131, e93-e93.	7.6	17
64	Development of a patient-centred conceptual framework of health-related quality of life in neuromyelitis optica: a qualitative study. <i>Health Expectations</i> , 2017, 20, 47-58.	2.6	15
65	Neuromyelitis optica - an update: 2007-2009. <i>Annals of Indian Academy of Neurology</i> , 2009, 12, 231.	0.5	14
66	Neuromyelitis optica in patients with increased interferon alpha concentrations. <i>Lancet Neurology</i> , The, 2020, 19, 31-33.	10.2	14
67	Autoimmune encephalitis (NMDAR antibody) in a patient receiving chronic post-transplant immunosuppression. <i>Practical Neurology</i> , 2018, 18, 320-322.	1.1	13
68	The Role of Plasma Exchange in the Treatment of Refractory Autoimmune Neurological Diseases: a Narrative Review. <i>Journal of Neuroimmune Pharmacology</i> , 2021, 16, 806-817.	4.1	13
69	Mycophenolate for persistent complex regional pain syndrome, a parallel, open, randomised, proof of concept trial. <i>Scandinavian Journal of Pain</i> , 2018, 18, 29-37.	1.3	12
70	No strong HLA association with MOG antibody disease in the UK population. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1502-1507.	3.7	12
71	Diagnostic procedures in suspected attacks in patients with neuromyelitis optica spectrum disorders: Results of an international survey. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102027.	2.0	11
72	Emotional facial paresis in temporal lobe epilepsy: its prevalence and lateralizing value. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2003, 12, 60-64.	2.0	10

#	ARTICLE	IF	CITATIONS
73	Inflammation or neoplasm? Another side to the story. <i>Clinical Neurology and Neurosurgery</i> , 2006, 108, 811-812.	1.4	10
74	Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). <i>BMJ Open</i> , 2020, 10, e035397.	1.9	10
75	Seasonal distribution of attacks in aquaporin-4 antibody disease and myelin-oligodendrocyte antibody disease. <i>Journal of the Neurological Sciences</i> , 2020, 415, 116881.	0.6	10
76	Health utilities and costs for neuromyelitis optica spectrum disorder. <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, 159.	2.7	10
77	Compression of the Deep Motor Branch of the Ulnar Nerve. <i>Archives of Neurology</i> , 2005, 62, 826.	4.5	9
78	Treatment of myelin oligodendrocyte glycoprotein immunoglobulin-associated disease. <i>Clinical and Experimental Neuroimmunology</i> , 2021, 12, 22-41.	1.0	9
79	Opsoclonus-myoclonus syndrome associated with a nasopharyngeal tumor in an adult: a case report. <i>Journal of Medical Case Reports</i> , 2015, 9, 128.	0.8	8
80	Solitary sclerosis: Progressive neurological deficit from a spatially isolated demyelinating lesion: A further report. <i>Journal of Spinal Cord Medicine</i> , 2015, 38, 551-555.	1.4	8
81	Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103080.	2.0	7
82	A Case of Neuromyelitis Optica With Gadolinium-Enhancing Brain Lesions and Parinaud Syndrome. <i>Archives of Neurology</i> , 2009, 66, 138.	4.5	6
83	An unusual case of 'itchy paralysis': neuromyelitis optica presenting with severe neuropathic itch. <i>Practical Neurology</i> , 2015, 15, 149-151.	1.1	6
84	If they are OK, we are OK: the experience of partners living with neuromyelitis optica. <i>Disability and Rehabilitation</i> , 2017, 39, 1279-1286.	1.8	6
85	Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 589-590.	1.9	5
86	Common variable immunodeficiency with granulomatous-lymphocytic interstitial lung disease and preceding neurological involvement: a case-report. <i>BMC Pulmonary Medicine</i> , 2020, 20, 205.	2.0	5
87	Longitudinally extensive myelitis in MS mimicking neuromyelitis optica. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2017, 4, e333.	6.0	4
88	Genetic variations within the OPA1 gene are not associated with neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2012, 18, 240-243.	3.0	1
89	Tonic spasms and short myelitis in an elderly woman: unique onset of neuromyelitis optica. <i>Practical Neurology</i> , 2015, 15, 463-465.	1.1	1
90	Progressive myelin oligodendrocyte glycoprotein-associated demyelination mimicking leukodystrophy. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1481-1484.	3.0	1

#	ARTICLE	IF	CITATIONS
91	Current Disease-Modifying Therapeutic Strategies in Multiple Sclerosis. Blue Books of Neurology, 2010, , 284-303.	0.1	0
92	070â€¦ What is seronegative neuromyelitis optica spectrum disorder?. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A34.2-A34.	1.9	0